High tumor mutational burden — the number of mutations found inside cancer cells — may not generalize as an accurate biomarker across diverse cancer patient populations, researchers report. The results could have important implications for clinical decision-making regarding treatment with immune checkpoint inhibitors (ICIs), a type of immunotherapy.
